Sun Pharma Q4 Results: Gross Sales up 10.1% YoY; Net Profit up 27.8%

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00


Sun Pharma’s Q4FY24 is a testament to the company’s growth in the quarter. Its gross sales came to ₹11813.3 Crore, up 10.1% YoY, while its EBITDA stood at ₹3035.2 Crore. Details here.

5 Key Financial Highlights

Sun Pharma's Q4FY24 results have shown impressive figures demonstrating strong performance across various metrics. Here are key highlights from the Sun Pharma Q4 results:

  • Q4 Gross sales at ₹11813.3 Crore, up by 10.1% YoY
  • Q4 EBITDA at ₹3035.2 Crore up 8.3% 
  • Q4 EBITDA Margin at 25.3% vs 25.6% during Q4FY23
  • Q4 Adjusted net profit at ₹2756.2 Crore, up 27.8%
  • FY24 Gross sales at ₹47758.5 Crore, up 10.4%

Additional ReadSun Pharma Share Price

Key Business Updates:

  • The Board of Directors recommended a total dividend for FY24 of ₹13.5 per share 
  • Sun Pharma’s India formulation sales for the quarter came at ₹3707.8 Crore, up 10.2% 
  • In this quarter itself, the company also made R&D investments at 900 Crore compared to ₹666 Crore in Q4FY23
  • Sun Pharma has also been ranked No.1 with a market share of 8.5% in ₹1,97,000 Crore Indian pharmaceutical market as per AIOCD AWACS MAT Mar-2024 reports.

  • As per the SMSRC MAT Feb-2024 report, Sun Pharma has also been ranked No.1 by prescriptions with 12 different doctor categories
  • For Q4FY24, the company also launched 9 new products in the Indian market.

Profitability Analysis:

Apart from the numbers that are coming to the fore when it comes to the Q4FY24 results of Sun Pharma, there are a lot of details and insights that one can gain into the profitability of the company. Here is a list of some of those insights: 

  1. Formulation sales for the company in the US for the entirety of FY24 were US$ 1,854, million. This saw a growth of 10.1% over the same period last year
  2. Sun Pharma’s formulation sales in Emerging Markets for the entirety of FY24 stood at US$ 1,041 million. This saw a growth of 5.9% over the same period last year.
  3. In the Rest of the World or RoW market, the company’s formulation throughout FY24 stood at US$ 811 million, up 7.8% over the same period last year.
  4. Sun Pharma’s external sales of API or Active Pharmaceutical Ingredients were at ₹415.8 Crore for Q4FY24, up by 7.9%

Major Operational Metrics - Consolidated Q4 (FY 2023-24) Financial Results of Sun Pharma (in ₹ Crore)


For Quarter Ended

For Year Ended






Revenue from Operations






Profit before tax 






Profit for the period






Additional ReadQuarterly Results

The Future of Sun Pharma

Sun Pharma has seen significant growth both in its Q4FY24 and in the entirety of FY2024. But there is not much more the company is up to. The company has stated that it has 6 molecules that are ready to undergo clinical studies soon. Other than this, when it comes to the US market, Sun Pharma has a comprehensive product offering that already consists of 531 approved ANDAs. The filings for 104 ANDAs however await US FDA approval. The company is positive though that 29 have already been approved tentatively. To add to this, Sun Pharma’s portfolio also includes 51 approved NDAs while 14 NDAs await US FDA approval. In Q4 itself, the company was able to file 11 ANDA out of which 2 approvals were received. With all this in mind, the company does look well on its way to a profitable FY25.

Additional ReadItc Q4 Results

About The Company:

Sun Pharmaceutical Industries Limited or Sun Pharma as it is known, was established in 1983 in Vapi, Gujarat by Dilip Shanghvi. At that time, the company had only five psychiatry products and worked with only a two-person marketing team. Sun Pharma, today leads the way in the country in its share of prescriptions and works with 12 classes of doctors in the country. The company is an Indian multinational pharmaceutical company and is now headquartered in Mumbai.


With Sun Pharma’s Q4FY results coming to the fore, it can be seen that the company has achieved significant growth both in the year and in the quarter. With its profit, sales, and EBITDA growing and its significance in the internal market also increasing with each passing quarter, FY25 might just be bigger for the company in terms of recognition and gains.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here:

Share this article: 

Frequently Asked Questions

Is the result of ITC’s Q4 good?

Answer Field

In Q4 FY24, ITC has done remarkably well, with key segment revenues up (Hotel, FMCG, and Cigarettes) driving overall Revenue growth for the quarter. For Q4, Gross Revenue was at ₹17,572 Cr, up by 2.0% YoY.

Based on ITC’s Q4 results, what will the future of the Company’s business look like?

Answer Field

With the prediction of a normal monsoon and a boost in macroeconomic indicators, the future of ITC appears optimistic with new units commencing business and segments being expanded to meet growing demand.

Did ITC announce any new initiatives or launches in terms of its business in its Q4 results?

Answer Field

ITC Q4 results have proved the Company’s underlying operational excellence, and the Company’s strides to make it a world-class player in all its segments. With new hotels opened and new launches in its FMCG segment, the Company strives to make a mark. Recently, the Company has forged many collaborations to promote its products and these augur well for its branding across its key segments.

No Result Found

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

7 Lac+ Users


4.5+ App Rating


4 Languages


₹ 3800 Cr MTF Book